Sowell Financial Services
CRVS icon

Sowell Financial Services’s Corvus Pharmaceuticals CRVS Stock Holding History

Sowell Financial Services’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224K Sell
14,975
-25
-0.2% -$347 0.01% 1012
2026
Q1 		$219K Sell
15,000
-2,000
-12% -$31.9K 0.01% 995
2025
Q4 		$131K Buy
17,000
+5,000
+42% +$39.4K ﹤0.01% 1072
2025
Q3 		$88.4K Hold
12,000
– – ﹤0.01% 1043
2025
Q2 		$48K Hold
12,000
– – ﹤0.01% 1027
2025
Q1 		$38.2K Buy
+12,000
New +$56.5K ﹤0.01% 997

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Sowell Financial Services's CRVS Position: Q2 2026 in Review

Sowell Financial Services reduced its Corvus Pharmaceuticals (CRVS) stake by 0.17% in Q2 2026, selling an estimated $347 and leaving 14,975 shares worth $224K. The position accounts for 0.01% of the portfolio, ranked #1012.

Sowell Financial Services first reported a position in CRVS in Q1 2025 and has held it in 6 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Sowell Financial Services held 14,975 shares of Corvus Pharmaceuticals worth $224K as of Q2 2026.
  • Sowell Financial Services sold 25 Corvus Pharmaceuticals shares in Q2 2026, an estimated $347.
  • Corvus Pharmaceuticals made up 0.01% of Sowell Financial Services's portfolio in Q2 2026, its #1012 holding.
  • Sowell Financial Services first reported a position in Corvus Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Sowell Financial Services's 13F filing for Q2 2026, filed 20 Jul 2026.